抗消化性溃疡药使用情况统计分析——基于“基药”与“基保”目录的差异视角  

Statistical Analysis on the Usage of Anti-Ulcer Drugs of Digestive Tract ——Based on the Perspective of Difference between the Directories of "National Essential Drugs" and "Basic Medical Insurance Drugs"

作　　者：高锦娟[1] 池明建[2] 胡世明[3] 康洽福[4] 

机构地区：[1]福建中医药大学附属第二人民医院,福州350003 [2]三明市第二医院,三明366000 [3]闽江学院公共经济学与金融学系,福州350108 [4]福建省医疗保险管理中心铁路分中心,福州350013

出　　处：《中国医疗保险》2015年第4期54-57,共4页China Health Insurance

摘　　要：本文通过分析福州地区11家二甲及以上定点医院住院医保患者抗消化性溃疡药使用情况。调取2014年度使用抗消化性溃疡药计2153份住院数据,根据是否国家基本药物、是否福建省基本医疗保险药品目录分别统计用药金额、DDDs、DDC等不同指标的统计对比,提出了国家基本药物目录与基本医疗保险药品目录应相互衔接;目录修订应考虑临床实际应用情况;医保经办机构、医疗监管部门、医疗机构要协同做好PPIs合理用药工作的建议。By reviewing the usage of anti-ulcer drugs of digestive tract in hospitalized patients of 11 Second-or higher level designated hospitals of Fujian Medical Insurance Management Center in Fuzhou area, we obtained 2153 hospitalization data in 2014, to compare the amounts of medication, DDs, DDC and some other index according to the Directory of “national essential drugs” or the Directory of“local basic medical insurance”. Based on the results of comparison, we suggest that national essential drugs directory and basic medical insurance drugs directory should be connected; drug directory revision should consider clinical and practical application; medical insurance agencies, health supervision departments and medical institutions should cooperate in PPIs rational using of medicine.

关 键 词：抗消化性溃疡药 质子泵抑制剂 国家基本药物 基本医疗保险 

分 类 号：R95[医药卫生—药学]